In the past week, ALT stock has gone down by -15.84%, with a monthly decline of -14.16% and a quarterly plunge of -23.06%. The volatility ratio for the week is 7.19%, and the volatility levels for the last 30 days are 9.19% for Altimmune Inc The simple moving average for the last 20 days is -9.55% for ALT stock, with a simple moving average of 50.91% for the last 200 days.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
ALT has 36-month beta value of 0.09. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALT is 70.17M, and currently, short sellers hold a 17.83% ratio of that float. The average trading volume of ALT on April 09, 2024 was 5.61M shares.
ALT) stock’s latest price update
The stock of Altimmune Inc (NASDAQ: ALT) has decreased by -5.28 when compared to last closing price of 9.09. Despite this, the company has experienced a -15.84% fall in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-01 that Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that’ll help you shed weight.
Analysts’ Opinion of ALT
Many brokerage firms have already submitted their reports for ALT stocks, with Goldman repeating the rating for ALT by listing it as a “Neutral.” The predicted price for ALT in the upcoming period, according to Goldman is $13 based on the research report published on January 24, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ALT reach a price target of $6, previously predicting the price at $20. The rating they have provided for ALT stocks is “Neutral” according to the report published on March 22nd, 2023.
Goldman gave a rating of “Buy” to ALT, setting the target price at $20 in the report published on December 01st of the previous year.
ALT Trading at -12.97% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.98% of loss for the given period.
Volatility was left at 9.19%, however, over the last 30 days, the volatility rate increased by 7.19%, as shares sank -17.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.22% lower at present.
During the last 5 trading sessions, ALT fell by -15.84%, which changed the moving average for the period of 200-days by +105.49% in comparison to the 20-day moving average, which settled at $9.43. In addition, Altimmune Inc saw -23.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Drutz David, who purchase 300 shares at the price of $2.88 back on Aug 15 ’23. After this action, Drutz David now owns 29,785 shares of Altimmune Inc, valued at $862 using the latest closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -196.03 for the present operating margin
- -76.88 for the gross margin
The net margin for Altimmune Inc stands at -203.67. The total capital return value is set at -0.42. Equity return is now at value -46.63, with -42.36 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -112.98. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 3630.87.
Currently, EBITDA for the company is -83.03 million with net debt to EBITDA at 1.72. When we switch over and look at the enterprise to sales, we see a ratio of 1117.19. The receivables turnover for the company is 0.09for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.25.
Conclusion
To put it simply, Altimmune Inc (ALT) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
